ZNF226

Across TCGA pan-cancer cohorts, ZNF226 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ZNF226 data layer compared with 20 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher ZNF226 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZNF226 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LIHC, UCEC, and PRAD are the cancer types where ZNF226 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.081	0.547	<.001	27	view →
UCEC	DFS	Median	All	0.973	0.827	.015	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LGG	OS	Median	All	0.306	0.799	.009	3	view →
SKCM	OS	Median	III,IV	0.529	0.846	.006	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ZNF226–LIHC (DFS)

Open the LIHC breakdown →